{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-001597","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.014945+00:00","generated_at":"2026-05-15T09:25:26.899090+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion","bullets":["At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).","Proposal to increase authorized shares from 9M to 59M failed: 38.2% for, 61.8% against.","Proposal to expand evergreen provision of 2024 equity plan to 10% fully diluted failed: 40.7% for, 59.3% against.","Neither proposal received the simple majority required for approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-001597","json":"https://secwatch.observer/filing/0001178913-26-001597.json","markdown":"https://secwatch.observer/filing/0001178913-26-001597.md","text":"https://secwatch.observer/filing/0001178913-26-001597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326001597/0001178913-26-001597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326001597/zk2634902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:25:26.899090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}